The study focused on the use of paxalisib, an oral medication that inhibits both PI3K and mTOR, alongside radiation therapy for patients with brain metastases from solid tumors that have a PI3K pathway mutation.

Lutris Pharma has published positive results from a phase 1/2 clinical trial of their lead compound, LUT014.

Sairiyo Therapeutics Inc., has begun regulatory and clinical development to assess the potential of its patented enteric-coated cepharanthine (PD-001) for treating oncology and infectious diseases.

Early findings from a study involving 472 infants aged nine months show that a new vaccine candidate, Shigella4V (S4V), developed by LimmaTech, has a good safety record and is well tolerated.

Ashvattha Therapeutics has enrolled its first patient in an expanded Phase 1/2 trial of 18F-OP-801, an imaging agent designed to cross the blood-brain barrier and target neuroinflammation.

A clinical trial is currently underway to evaluate the combination treatment of BNT316/ONC-392, an anti-CTLA-4 antibody, with lutetium (177Lu) vipivotide tetraxetan (Pluvicto®).

Biotechnology firm Ocugen, Inc. has reached a significant milestone in its clinical trial for a gene therapy treatment, OCU410ST, aimed at Stargardt disease.

Biotechnology firm Celcuity Inc. has initiated a Phase 1b/2 clinical trial, known as CELC-G-201, to test the efficacy and safety of gedatolisib combined with Nubeqa® (darolutamide).

Elevation Oncology, a company listed on the Nasdaq (ELEV), is advancing its Phase 1 clinical trial for EO-3021, a novel antibody drug conjugate (ADC), by expanding the study to include Japan.

The SCOPE 2024 conference, inaugurated by Fareed Melhem of Medidata Solutions, emphasized the significance of integrating patient care with clinical research.

San Diego-based PassPort Technologies, Inc. (PPTI) has launched a Phase 1 clinical trial in the United States for the Zolmitriptan PassPort® system, which employs a unique transdermal microporation system.

AI-driven drug discovery firm Expert Systems has reached a key milestone in collaboration with Eilean Therapeutics, having completed a Phase 1 clinical trial for lomonitinib, a targeted pan-FLT3/IRAK4 inhibitor.